Firm Secures Settlement in High Profile Dispute Over Arthritis Drug Rights
Law360, New York (April 15, 2011) -- Merck & Co. Inc. said Friday it will pay Johnson & Johnson $500 million to end a dispute over rights to two arthritis drugs resulting from Merck's merger with Schering-Plough Corp., and that the two companies plan to share marketing rights.
Merck added it would hand J&J's Janssen unit exclusive marketing rights to the drugs Remicade and Simponi in Canada, Central and South America, the Middle East, Africa, and Asia Pacific on July 1, while retaining marketing rights throughout Europe, Russia and Turkey.
The deal ends an arbitration J&J requested in May 2009 to sever an agreement between subsidiary Centocor Ortho Biotech Inc. and Schering-Plough for rights to market and sell the arthritis drugs.
To read the full article from Law360, please click here.